Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma

Michihisa Moriguchi; Keiichiro Okuda; Go Horiguchi; Seita Kataoka; Yuya Seko; Kanji Yamaguchi; Takeshi Nishimura; Hideki Fujii; Yasuhide Mitsumoto; Masami Miyagawa; Toshihiko Kirishima; Shinya Okishio; Tasuku Hara; Hiroki Ishikawa; Yasuyuki Nagao; Masayasu Jo; Michiaki Ishii; Saiyu Tanaka; Norihito Yamauchi; Hironori Mitsuyoshi; Tomoki Nakajima; Hiroyoshi Taketani; Kota Yano; Masahiro Arai; Atsushi Umemura; Yoshito Itoh

doi:10.1111/liv.15918

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

This study aimed to determine the safety and efficacy of atezolizumab + bevacizumab therapy in hepatocellular carcinoma patients receiving anti-platelet agents or anticoagulants.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Moriguchi et al. (2024) studied this question.

synapsesocial.com/papers/68e6635ab6db6435875f0013 https://doi.org/10.1111/liv.15918

View at Publisher

Ask AI

Bookmark

Share

Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma

Ask about this paper

Abstract

Discussion

Cite This Study

Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading